# HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Source: https://onco.cc/trials/nct07296341/  
OnCo record `nct07296341` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Adebrelimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07296341 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 60 participants planned, started 2026-01-08 and due to reach its primary completion in 2027-10. Interventions recorded: HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine and HRS-4642;nab-paclitaxel; gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07296341
- Phase: 1/2
- Setting: A Phase IB/II Study To Evaluate the Safety, Tolerability, and Preliminary Efficacy of HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07296341: https://clinicaltrials.gov/study/NCT07296341

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07296341.json